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Abstract
Background: Despite the clinical outcomes of ovarian stimulation with either GnRH-agonist or
GnRH-antagonist analogues for in vitro fertilization (IVF) being well analysed, the effect of
analogues on oocyte/embryo quality and embryo development is still not known in detail. The aim
of this case-control study was to compare the efficacy of a multiple-dose GnRH antagonist protocol
with that of the GnRH agonist long protocol with a view to oocyte and embryo quality, embryo
development and IVF treatment outcome.
Methods: Between October 2001 and December 2008, 100 patients were stimulated with human
menopausal gonadotrophin (HMG) and GnRH antagonist in their first treatment cycle for IVF or
intracytoplasmic sperm injection (ICSI). One hundred combined GnRH agonist + HMG (long
protocol) cycles were matched to the GnRH antagonist + HMG cycles by age, BMI, baseline FSH
levels and by cause of infertility. We determined the number and quality of retrieved oocytes, the
rate of early-cleavage embryos, the morphology and development of embryos, as well as clinical
pregnancy rates. Statistical analysis was performed using Wilcoxon's matched pairs rank sum test
and McNemar's chi-square test. P < 0.05 was considered statistically significant.
Results: The rate of cytoplasmic abnormalities in retrieved oocytes was significantly higher with
the use of GnRH antagonist than in GnRH agonist cycles (62.1% vs. 49.9%; P < 0.01). We observed
lower rate of zygotes showing normal pronuclear morphology (49.3% vs. 58.0%; P < 0.01), and
higher cell-number of preembryos on day 2 after fertilization (4.28 vs. 4.03; P < 0.01) with the use
of GnRH antagonist analogues. The rate of mature oocytes, rate of presence of multinucleated
blastomers, amount of fragmentation in embryos and rate of early-cleaved embryos was similar in
the two groups. Clinical pregnancy rate per embryo transfer was lower in the antagonist group than
in the agonist group (30.8% vs. 40.4%) although this difference did not reach statistical significance
(P = 0.17).
Conclusion: Antagonist seemed to influence favourably some parameters of early embryo
development dynamics, while other morphological parameters seemed not to be altered according
to GnRH analogue used for ovarian stimulation in IVF cycles.
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The first IVF cycles were performed in natural unstimu-
lated cycles [1]. Today gonadotrophins are administered
to induce multiple follicular development and controlled
ovarian hyperstimulation. During ovarian stimulation
gonadotrophin-releasing hormone (GnRH) analogues are
co-administered in order to prevent premature luteinizing
hormone (LH) surges. Premature LH surges are observed
in about 20% of stimulated cycles without using GnRH
analogues [2,3]. Avoiding the adverse effects of elevated
LH-levels, first GnRH agonist analogues were used to sup-
plement the gonadotrophin stimulation. The continuous
administration of GnRH agonists causes gonadotrophin
suppression through down-regulation and desensitiza-
tion of the GnRH receptors in the pituitary gland after an
initial short period of gonadotrophin hypersecretion [4].
In 1985 the long protocol of GnRH agonists was reported
[5]. Among other types of effective combined GnRH-ago-
nist + gonadotrophin protocols, the long protocol proved
to be the first choice of stimulation [6].
A decade later the first studies about the third, clinical
adaptable generation of GnRH-antagonist analogues
appeared [7,8]. GnRH antagonists (cetrorelix and ganire-
lix) cause immediate and rapid gonadotrophin suppres-
sion by competitive antagonism of the GnRH receptor in
the pituitary without an initial period of gonadotrophin
hypersecretion. Several advantageous effects (shorter
stimulation period, lower risk of ovarian hyperstimula-
tion syndrome) of cetrorelix were established [9], and
these effects seemed to be independent from the type of
antagonist used for LH-suppression [10]. Although com-
bined GnRH antagonist and gonadotrophin stimulation
represents an effective alternative to classical protocol
with GnRH agonists, still the GnRH-agonist long protocol
remained the first choice in the most IVF centres [11].
The quality of oocytes [12-15] and developing preem-
bryos [16,17] is one of the most relevant factors determin-
ing the success of an IVF treatment. In order to improve
the efficacy of the treatment, either more embryos at a
time will be transferred or a well-established stimulation
protocol and embryo-selection procedure with lower
number of transferred embryos is practised. There is the
need to transfer less but more viable embryos to reduce
the occurrence of multiple pregnancies. As a result of
improved fertilization and embryo culture techniques,
patients may produce more good-quality embryos and
have higher implantation and pregnancy rates. As ovarian
stimulation protocol is one of the eligible factors during
an IVF treatment, its embryo quality influencing effects
are necessary to know. Since 2000 the comparison of
GnRH agonist vs. GnRH antagonist protocols has been
well analyzed in clinical studies [18-20], most of them
focused on the clinical outcome of the two protocols, nev-
ertheless the effects of the GnRH analogues on oocyte-
and embryo-quality and on embryo development are still
not known in detail.
The aim of our study was to verify the impact of the mul-
tiple dose protocol of GnRH antagonists in comparison
with the long protocol of GnRH agonists on oocyte-,
embryo quality and embryo development in IVF/ICSI
cycles.
Methods
Subject groups
This retrospective case control study was performed with
data of patients entering the IVF/ICSI program of the Divi-
sion of Assisted Reproduction, First Department of
Obstetrics and Gynecology, Semmelweis University
School of Medicine, Budapest, Hungary. All IVF cycles
performed between July 2001 and December 2008 were
included in the antagonist-group (ANT) when GnRH
antagonist was used during ovarian stimulation in the
first IVF treatment cycle of the patient.
In selecting the control agonist-group (AG), it was deter-
mined to vary in only one clinical parameter from the
antagonist group: the use of either GnRH agonist or
GnRH antagonist during ovarian stimulation. All other
clinical parameters (female age, body mass index [BMI],
basal follicle-stimulating hormone [FSH] level, indication
for IVF treatment, type of gonadotrophin used for ovarian
stimulation) were matched to the antagonist pairs.
The study includes data from the first IVF/ICSI cycle of
each patient only. Cancelled stimulations (no oocyte
retrieval was performed) and IVF treatments completed
with preimplantation genetic diagnosis (PGD) were
excluded from the study.
All patients entering our department signed informed
consent accepting their data will be used for scientific
evaluations.
Ovarian stimulation
In the antagonist group (ANT) multiple dose GnRH
antagonist regimen (Lübeck protocol) was used for ovar-
ian stimulation: 0.25 mg/day cetrorelix (Cetrotide;
Serono, Rome, Italy) or ganirelix (Orgalutran; Organon,
Oss, The Netherlands) was administrated from the fifth
day of ovarian stimulation or from the presence of a folli-
cle with 14 mm diameter. In the agonist group (AG) the
long protocol of GnRH agonist was used: pituitary desen-
sitization was achieved with GnRH agonist triptorelin
(Decapeptyl; Ferring, Kiel, Germany), at a dose of 0.1 mg/
day from the midluteal phase of the cycle preceding the
treatment cycle.
Human menopausal gonadotrophin (HMG) (Menogon;
Ferring or Menopur; IBSA, Lugano, Switzerland or Meri-Page 2 of 8
(page number not for citation purposes)
Reproductive Biology and Endocrinology 2009, 7:103 http://www.rbej.com/content/7/1/103onal; IBSA) or high-purified urofollitropin (Fostimon HP;
IBSA) was used for ovarian stimulation in both groups,
which was monitored 1-2 times daily by estradiol meas-
urements and transvaginal ultrasound examination. Type
of gonadotrophin used for ovarian stimulation was
always the same in one stimulation cycle; we have neither
changed nor used gonadotrophins in line with an other
type during one cycle.
Ovulation was induced with 5,000-10,000 IU of HCG
(Profasi; Serono or Choragon; Ferring) when at least one
follicle with a diameter of ≥18 mm and three or more fol-
licles with a diameter of ≥16 mm were present and serum
estradiol levels reached 2-300 pg/ml per ≥10 mm follicle.
Transvaginal ultrasound-guided oocyte retrieval was per-
formed 36 hours after HCG administration. 600 mg
micronized progesterone (Utrogestan; Besins-Iscovesco
Pharmaceuticals, Paris, France) intravaginally was used
daily for luteal phase support.
Sperm preparation and fertilization
Progressive motile sperms for insemination were isolated
by swim up technique or by a two-layer density gradient
centrifugation according to the quality of the native
semen sample.
Conventional IVF was performed routinely 6 hours after
oocyte retrieval (day 0). Motile sperm count used for
insemination was 100-500.000 according to the patient
age and semen quality. Following 16-18 hours coincuba-
tion oocytes were mechanically denuded of their cumulus
cells and placed into culture media individually in sepa-
rate wells of a four-well dish.
ICSI treatment was performed 5-8 hours after oocyte
retrieval. The indications for ICSI were (A) <1 million pro-
gressive motile sperm after preparation and/or (B) ≤4
oocytes retrieved. Denudation of oocytes was performed
by gentle pipetting after a short incubation in 80 IU/ml
hyaluronidase. After sperm injection, the oocytes were
placed into culture media individually.
Maturity of oocytes and cytoplasmic abnormality of
oocytes were examined before sperm injection. Cytoplas-
mic alterations were rated abnormalities if oocytes con-
tained large (≥10 μm) vacuoles or excessive granularity.
Embryo culture
Embryos were cultured in home made Whittingham's T6
culture media [21] supplemented with 15% maternal
serum or Vitrolife IVF culture media. Zygotes and embryos
were cultured individually in 1 ml of culture media under
5% CO2 in air until embryo transfer was performed.
Zygote and embryo assessment
16 to 20 hours after conventional IVF or ICSI (day 1) nor-
mal fertilization was confirmed by the presence of two
pronuclei. At the same time pronuclear morphology were
scored as it was described by Tesarik and Greco [22]:
number and alignment of nucleoli (nucleolar precursor
bodies, NPB) were evaluated and "Pattern 0" are called
normal pronuclear morphology zygotes. Zygotes were
examined again 22-25 hours after insemination or micro-
injection to determine whether pronuclear breakdown or
first cleavage had occurred. On day 2 at 40-48 hours
postinsemination embryos were assessed for cell number,
uniformity of blastomere size, amount of fragmentation
and incidence of the multinucleated blastomeres. The
morphology score given to the embryos was: 4 for regular
blastomeres, no fragments, and no multinucleated blast-
omeres; 3 for regular blastomeres, ≤20% fragments, and
no multinucleated blastomeres; 2 for unequal-sized blas-
tomeres or >20% fragments; 1 for unequal-sized blast-
omeres or >50% fragments; 0 for >80% fragmentation or
no visible blastomeres. Embryos were termed top quality
if their morphology score was 3 or 4 and they contained
at least four cells on day 2.
Embryo transfer and pregnancy
Our embryo transfer policy was the same in all of the
cycles: embryos with the highest cell number and the
highest grade were selected for embryo transfer. We trans-
ferred 1-3 embryos at once according to the age of the
patient and embryo quality. Four embryos were trans-
ferred if the patient was more than 40 years of age. Super-
numerous embryos with eligible morphology were
cryopreserved.
Clinical pregnancy was considered according to WHO
and ICMART (International Committee for the Monitor-
ing of ART) definition of it as it is recommended by
ESHRE: evidence of pregnancy by ultrasound visualisa-
tion of a gestational sac at gestational week 5-7.
Statistical analysis
The statistical analysis was performed by Statistica 8.0
Software (StatSoft Inc., Tusla, USA). Mann-Whitney U-test
or Wilcoxon's matched pairs rank sum test was used to
compare mean values and Pearson chi-square or McNe-
mar chi-square analysis for comparison of proportional
values. P < 0.05 was considered statistically significant.
Results
The two groups did not differ significantly with respect to
baseline characteristics. Mean patient age, BMI, basal FSH
concentration and cause of infertility was similar in the
two groups (Table 1).Page 3 of 8
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was similar in the two groups. The clinical parameters of
ovarian stimulation showed that significantly less
ampoules of HMG were needed in the ANT group than in
AG group and the length of stimulation was significantly
longer in the AG group (Table 2).
The number of follicles aspirated and oocytes retrieved
was significantly lower in the antagonist group than with
the use of the agonist. There was one cycle in the ANT
group and four cycles in the AG group where we could not
found oocytes at all. Rate of mature (MII) oocytes was
similar in the two groups. We observed higher rate of cyto-
plasmic abnormalities in retrieved oocytes in the antago-
nist group than in agonist cycles (Table 3).
The method of fertilization was similar in both groups,
ICSI was performed about three quarters of all cases. The
percentage of normal fertilized oocytes (2PN zygotes) was
similar in both groups independent of the method of fer-
tilization. Having significant less oocytes available for fer-
tilization in the antagonist group, the mean number of
normal fertilized oocytes were also lower in this group.
We observed higher rate of zygotes showing normal
nucleolar distribution with the use of GnRH agonist ana-
logues (Table 4).
Using antagonist GnRH analogue for stimulation, we
observed higher cell number of praeembryos on day 2
after fertilization, althought the higher rate of early-cleav-
age embryos did not reach statistical significance between
the two groups. Contrary to the dynamics of embryo
development, the percentage of top-quality embryos and
the rate of presence of multinucleated blastomers this day
seemed to be similar in the two groups, while the rate of
praeembryos' fragmentation was lower using antagonists
(Table 5).
Clinical pregnancy rates were in tendency lower in the
antagonist group than in the agonist group (per embryo
transfer P = 0.17 and per stimulation cycles P = 0.13),
implantation rates were also lower using antagonists
although these differences did not reach statistical signifi-
cance. The odds ratios for clinical pregnancy rate were per
transfer 0.65 (0.34-1.25) and per cycle 0.63 (0.33-1.20).
The mean number of supernumerous embryos appropri-
ate for cryopreservation seemed to be similar in the two
groups (Table 6).
Discussion
The success of an IVF/ICSI treatment depends substan-
tially on the quality of transferred embryos. Among
numerous factors affecting embryo quality, ovarian stim-
ulation is an eligible and adjustable one. Despite the
established clinical impact of different stimulation proto-
cols, analysis of ovarian stimulation on quality of oocytes
and developing embryos is not well known yet.
Table 1: Baseline characteristics of the patients
Baseline parameters GnRH antagonist GnRH agonist P value
Female age (year) 33.6 (± 5.6) 33.7 (± 5.6) 0.74
BMI (kg/m2) 23.0 (± 3.8) 22.9 (± 3.7) 0.41
Basal FSH (IU/L) 7.4 (± 4.1) 6.8 (± 1.8) 0.07
Cause of infertility:
tubal factor 22 22
other female origin 5 5
male factor 35 35
both female and male factor 14 14
unknown origin 24 24
Total 100 100
BMI: body mass index; FSH: follicle stimulating hormone
Table 2: Characteristics of ovarian stimulation
Ovarian stimulation GnRH antagonist GnRH agonist P value
Type of gonadotrophin used for stimulation
high purified urofollitropin 24 17 0.29
human menopausal gonadotrophin 76 83
Total 100 100
number of HMG ampoules (mean + SD) 25.9 (± 15.1) 31.5 (± 15.8) < 0.01
Length of stimulation (days) (mean + SD) 8.9 (± 1.4) 10.5 (± 1.3) < 0.01
HMG: human menopausal gonadotrophinPage 4 of 8
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antagonists and gonadotrophins has also been available,
the GnRH-agonist long protocol remained the first choice
in most IVF centres [11] as it is in our IVF department, too.
We choose GnRH antagonist protocols at the first IVF
cycle of the patient almost exclusively when the duration
of the pretreatment and ovarian stimulation is limited;
this explains the small number of patients in our study in
spite of the relatively long trial period.
As previous studies reported [19,20], we also showed that
patients need less HMG ampoulles and the length of stim-
ulation is shorter with the use of GnRH antagonists proto-
col. We aspirated significantly more follicles and we
retrieved significantly more oocytes with the use of GnRH
agonist; most of the comparative studies of GnRH ana-
logues had similar results [9,19,20].
These clinical aspects have been evaluated in several stud-
ies, but only a recent study focused on the differences in
embryo quality according to the type of gonadotrophin
used for ovarian stimulation [23].
Like in some previous studies, there was no significant dif-
ference between the rate of mature metaphase II oocytes
in the two groups in our study, however this parameter
was examined only by a few workgroups and one study
was made on a special group of non-obese PCOS patients
[18,19,24].
Several studies focused on the role of oocyte quality in
predicting treatment outcome. Granularity in the periv-
itelline space seems to be a physiological phenomenon in
oocytes and it could be enhanced by exposure to high dos-
ages of gonadotrophins [25]. In a recent study stimulation
protocol prooved to influence significantly the zona pel-
lucida score (agonist protocol resulted in better score
compared to the antagonist one) [26]. The presence of
intracytoplasmic abnormalities can refer to the quality of
the oocyte [12,13]. Otsuki et al. confirmed pronucleus
sized translucent vacuoles in oocytes as tubular-type
smooth endoplasmic reticulum clusters (sERCs) [14].
sERC positive oocytes were observed more frequent in
GnRH agonist short protocols compared to long ones.
Comparing GnRH agonist long proctocol to GnRH antag-
onist cycles in our study we have also found significantly
less oocytes with cytoplasmic abnormalities after admin-
istrating GnRH agonists in long protocol.
According to the method of fertilization (IVF or ICSI)
there was no significant difference between the two
groups in the rate of normally fertilized oocytes; this
parameter was similar in both groups independent of the
method of fertilization. In previous studies the rate of the
normally fertilized oocytes was examined during conven-
tional IVF and ICSI treatments together only: cumula-
tively there was no significant difference between the two
groups [20]. However these parameters were similar in the
two groups, accordingly the lower count of retrieved
Table 3: Parameters of oocyte retrieval and of retrieved oocytes
Oocyte characteristics GnRH antagonist GnRH agonist P value
follicles aspirated (mean + SD) 9.0 (± 4.9) 11.2 (± 5.0) < 0.01
cycles where no oocytes were found 1/100 4/100 0.37
retrieved oocytes (mean + SD) 6.5 (± 4.0) 8.1 (± 4.3) < 0.01
mature (metaphase II.) oocytes
(ICSI only) (%)
87.2
(340/390)
88.4
(419/474)
0.58
oocytes with cytoplasmic abnormalities (ICSI only) (%) 62.1
(208/335)
49.9
(228/457)
< 0.01
Table 4: Rate of fertilization method, of normal fertilization and of nucleolar distribution
Fertilization GnRH antagonist GnRH agonist P value
ICSI frequency (%) 74.8
(74/99)
68.8
(66/96)
0.22
normal fertilization (all) (%) 55.9
(363/649)
60.4
(489/810)
0.09
normal fertilization (ICSI) (%) 57.7
(225/390)
59.9
(284/474)
0.51
normal fertilization (IVF) (%) 53.3
(138/259)
61.0
(205/336)
0.06
number of fertilized oocytes/cycle
(mean + SD)
3.7 (± 3.0) 5.1 (± 3.4) < 0.01
normal pronuclear morphology (%) 49.3
(176/357)
58.0
(280/483)
< 0.01Page 5 of 8
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was significantly lower in the antagonist cycles. Normal
nucleolar distribution was also significantly lower in the
antagonist group. This parameter has not been examined
yet in previous studies in view to the type of GnRH ana-
logue used for stimulation. The zygotes with normal pro-
nuclear morphology are supposed to develop most likely
top-quality embryos [27-29].
Dynamics of early embryonic development could reflect
the developmental potential of the embryo. The first
cleavage can be examined with the breakdown of the pro-
nuclear membrane (the start of the M phase of the first cell
cycle) and directly with the presence of cleavage, because
the duration of the M phase is relatively constant (3-4
hours) [30,31]. It is known that early cleavage is a strong
indicator of the quality and the viability of the embryos
[30,32,33], although a recent study showed higher
implantational potential for early-cleavage embryos only
with the use of GnRH agonists [34]. We observed signifi-
cantly higher number of blastomers in the antagonist
group on day 2, while the higher presence of early cleav-
age in this group did not reach statistical significance.
There was no significant difference in the rate of the top
quality embryos. (Embryo quality and development were
examined also on day 3 [64-72 hours postinsemination],
but only the results of day 2 are analyzed in this study,
because part of the embryos are used to be transferred on
day 2 already. Hence the results of day 3 would not be rep-
resentative in this study). Other studies had similar results
in the rate of the top quality embryos, but the early cleav-
age, the number of multinucleated blastomeres (multinu-
cleated embryos have poor implantation potential [35])
and the amount of fragmentation have not been yet exam-
ined during comparative studies of GnRH analogues.
The clinical pregnancy rate, which shows the effectiveness
of the treatments, was examined in all of the comparative
studies. Co-administrating GnRH agonists during gona-
dotrophin ovarian stimulation seems to result in higher
pregnancy rates, however this difference proved not to be
significant in most of the studies [19,20,24]. Despite of
the not significant difference in our study in pregnancy
rates, the presented odds ratios indicate higher pregnancy
rates by GnRH agonists. The higher number of cycles with
supernumerous embryos appropriate for cryopreservation
in the agonist group favours the patient avoiding a
repeated ovarian stimulation and oocyte retrieval proce-
dure in a contingent next treatment.
Conclusion
It seems that more oocytes can be retrieved, there is less
cytoplasmic abnormality in the mature oocytes, there are
more oocytes with normal fertilization and there are more
zygotes with normal pronuclear morphology after stimu-
lation with GnRH agonist analogues. In contrast, there are
more blastomeres in the embryos on day 2 when GnRH
antagonists were administered. While there was no signif-
icant difference between clinical pregnancy rates of the
Table 5: Characteristics of embryo development and embryo quality
Embryo development GnRH antagonist GnRH agonist P value
presence of early cleavage (%) 39.6
(108/273)
32.8
(139/424)
0.07
number of blastomers on day 2 4.28
(± 1.39)
4.03
(± 1.34)
< 0.01
top quality embryos on day 2 (%) 23.9
(84/351)
26.8
(128/477)
0.34
presence of multinucleated blastomers (%) 13.7
(49/357)
13.0
(62/477)
0.76
amount of fragmentation on day 2 (%) 15.2
(± 10.2)
17.3
(± 12.0)
< 0.01
Table 6: Clinical outcomes in the GnRH antagonist and GnRH agonist groups
Clinical outcome GnRH antagonist GnRH agonist P value
embryotransfer performed (%) 91.0 (91/100) 94.0 (94/100) 0.58
transferred embryos (mean + SD) 2.59 (± 0.87) 2.84 (± 0.83) 0.06
cryopreservation performed (%) 17.0 (17/100) 28.0 (28/100) 0.09
cryopreserved embryos (mean + SD) 4.29 (± 1.92) 4.64 (± 2.04) 0.57
clinical pregnancy rate (%)/ET 30.8 (28/91) 40.4 (38/94) 0.17
clinical pregnancy rate (%)/cycle 28.0 (28/100) 38.0 (38/100) 0.13
implatation rate (%) 19.1 (45/236) 20.6 (55/267) 0.67Page 6 of 8
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effects of the GnRH analogues on the quality of the
oocytes and the embryos may be equalized.
We hope the new advantages and disadvantages of the
GnRH analogues identified through this study can be the
principle starting further investigations to help the clini-
cian choose the appropriate medication for ovarian stim-
ulation in IVF/ICSI treatments.
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